Skip to main content
Indian Journal of Ophthalmology logoLink to Indian Journal of Ophthalmology
. 2016 Jun;64(6):459. doi: 10.4103/0301-4738.187676

Prostaglandin-associated periorbitopathy

Neha Shrirao 1, Mona Khurana 1, Bipasha Mukherjee 1,
PMCID: PMC4991179  PMID: 27488155

A 59-year-old gentleman with primary open-angle glaucoma was on topical bimatoprost 0.03% in the left eye since last 6 years. He presented with deepening of superior sulcus (arrow), periorbital fat atrophy, mild ptosis (a), and 2 mm of enophthalmos (b) in his left eye [Fig. 1], which are typically seen in prostaglandin-associated periorbitopathy (PAP). Comparison with old photographs taken before topical bimatoprost use showed the absence of any asymmetry between the eyes.

Figure 1.

Figure 1

(a) Presence of left eye upper eyelid ptosis with deep superior sulcus (arrow) compared to right eye. (b) “Worm's hole view” (Nafziger method) showing left eye mild enophthalmos

PAP, first reported in 2004, is caused by prolonged use of topical prostaglandin (PG) analogs.[1] It has been reported with the use of bimatoprost, travoprost, tafluprost, and latanoprost.[2,3,4] The classical features are as seen in our patient. PAP can appear as early as a month after the use of bimatoprost and is caused by fat atrophy, inhibition of adipocyte production, and differentiation of orbital fat due to PGF receptor stimulation by PG analogs.[2,5] Complex effects of PG analogs on levator muscle and Muller's muscle along with orbital fat are postulated to be responsible for ptosis.[2] PAP is reversed several months to years after discontinuation of the drug.[1,2]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  • 1.Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574–7. doi: 10.1097/01.opx.0000141791.16683.4a. [DOI] [PubMed] [Google Scholar]
  • 2.Kucukevcilioglu M, Bayer A, Uysal Y, Altinsoy HI. Prostaglandin associated periorbitopathy in patients using bimatoprost, latanoprost and travoprost. Clin Experiment Ophthalmol. 2014;42:126–31. doi: 10.1111/ceo.12163. [DOI] [PubMed] [Google Scholar]
  • 3.Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy with a latanoprost ophthalmic solution. Eye (Lond) 2014;28:1446–51. doi: 10.1038/eye.2014.224. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sakata R, Shirato S, Miyata K, Aihara M. Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution. Jpn J Ophthalmol. 2014;58:212–7. doi: 10.1007/s10384-013-0299-8. [DOI] [PubMed] [Google Scholar]
  • 5.Taketani Y, Yamagishi R, Fujishiro T, Igarashi M, Sakata R, Aihara M. Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy. Invest Ophthalmol Vis Sci. 2014;55:1269–76. doi: 10.1167/iovs.13-12589. [DOI] [PubMed] [Google Scholar]

Articles from Indian Journal of Ophthalmology are provided here courtesy of Wolters Kluwer -- Medknow Publications

RESOURCES